Logo

Bio-Thera Announces BLA Acceptance of Humira's Biosimilar (BAT1406) by China National Drug Administration (CNDA)

Share this

Bio-Thera Announces BLA Acceptance of Humira's Biosimilar (BAT1406) by China National Drug Administration (CNDA)

Shots:

  •  This BLA is for the treatment of RA- PsA- AS- CD- UC- chronic psoriasis- HS- and JIA
  •   The clinical study included (PK/PD) and Ph III trials in ankylosing spondylitis showing its safety- efficacy and quality
  •  Bio-Thera is developing 7 biosimilars including BAT1406- with Avastin biosimilar currently being assessed in a global Ph III trial

Ref: Businesswire | Image:  LinkedIn

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions